| ID | Sequence | Length | GC content |
|---|---|---|---|
| CCUUUCUACGCUGGGCCGGUUAUCGACCCGGCCCAGUGCGCAGGCGCGG… | 1061 nt | 0.6126 | |
| CCUUUCUACGCUGGGCCGGUUAUCGACCCGGCCCAGUGCGCAGGCGCGG… | 791 nt | 0.5689 | |
| CCUUUCUACGCUGGGCCGGUUAUCGACCCGGCCCAGUGCGCAGGCGCGG… | 648 nt | 0.5556 | |
| CCUUUCUACGCUGGGCCGGUUAUCGACCCGGCCCAGUGCGCAGGCGCGG… | 840 nt | 0.5690 | |
| AAGUAAGUAUCCCCACUUUCAGGGUAGCAUCCUCUUUCCCUAGUUAUUU… | 1528 nt | 0.5517 | |
| CCUUUCUACGCUGGGCCGGUUAUCGACCCGGCCCAGUGCGCAGGCGCGG… | 612 nt | 0.5637 | |
| CCUUUCUACGCUGGGCCGGUUAUCGACCCGGCCCAGUGCGCAGGCGCGG… | 788 nt | 0.5698 | |
| CCUUUCUACGCUGGGCCGGUUAUCGACCCGGCCCAGUGCGCAGGCGCGG… | 1064 nt | 0.6118 |
This gene encodes a member of a family of proteins containing a Bcl-2 homology domain 2 (BH2). The encoded protein is an anti-apoptotic factor that acts as an inhibitor of caspases 3 and 7 in the cytoplasm. In the nucleus, it binds to the p53 tumor suppressor protein, preventing its association with target genes. Overexpression of this gene has been detected in a number of different cancers. There is a pseudogene for this gene on chromosome 3. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2013]
A study in cultured human aortic endothelial cells demonstrated that the BCL2L12 mRNA was one of eleven most-significantly regulated transcripts at 24 hours post-irradiation, functioning as a marker to differentiate unirradiated (0 Gy) samples from those exposed to X-ray doses of 1-10 Gy [Chopra et al. DOI:10.1038/s41598-022-24051-6].